
Switching Therapies in HIV
An expert on HIV provides clinical insights on the rationale for switching therapies and ways to educate patients on treatment decisions.
Episodes in this series

BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following questions:
- What are the rapid start guideline recommendations for a patient taking injectable cabotegravir PrEP?
- When you initiate one of these guidelines recommended therapies, how often do you need to change that regimen based on laboratory results?
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.














































































































































































































































































































